@article{5270f2f3e020401184760515d9c8347e,
title = "Polo-like Kinase 4 inhibition: A strategy for cancer therapy?",
abstract = "In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.",
author = "Holland, {Andrew J.} and Cleveland, {Don W.}",
note = "Funding Information: We apologize to colleagues whose work was not discussed or cited owing to space constraints. Kevin Clutario is gratefully acknowledged for help preparing the figures. A.J.H. is funded by a Leukemia & Lymphoma Society special fellowship, Leukemia Research Foundation Research Grant, W.W. Smith Charitable Trust Research Grant, March of Dimes Basil O{\textquoteright}Conner Scholar Award, Pew Scholar Award, and a Kimmel Scholar Award. D.W.C. is funded by a grant (R01-GM29513) from the NIH and receives salary support from the Ludwig Institute for Cancer Research.",
year = "2014",
month = aug,
day = "11",
doi = "10.1016/j.ccr.2014.07.017",
language = "English (US)",
volume = "26",
pages = "151--153",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "2",
}